CIK 1382911LEI 5493008EJF1IXC1DOC52

Orexigen Therapeutics, Inc.

EDGAR filings

Customers

1 disclosed

Suppliers

None disclosed

Largest customer

99%

TAK · FY to 2015-12-31

Named-customer revenue

$24.2M

1 customer · FY to 2015-12-31

Latest period

Dec 31, 2015

10-K filed 2016-02-26

Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available) or federal dollars obligated. Each side is scaled on its own; dashed outlines are named without a figure. Click a band to open its source.

Customers 1

Companies Orexigen Therapeutics, Inc. discloses as major customers, as a share of Orexigen Therapeutics, Inc. revenue. 1 active, 0 lapsed.

Company	% of Orexigen Therapeutics, Inc. revenue	Est. revenue	Period	Trend	Status	Source
TAK TAKEDA PHARMACEUTICAL CO LTD	99%	$24.2M	FY 2015-12-31	−1.0pp	Active	10-K 2016-02-26
• the level of underlying demand for Contrave, wholesalers’ buying patterns with respect to Contrave, discounts given to certain Contrave customers, and Takeda’s ability to successfully market Contrave under our collaboration agreement; 10-K filed 2016-02-26 Period FY 2015-01-01 to 2015-12-31 (99%), FY 2014-01-01 to 2014-12-31 (100%), FY 2013-01-01 to 2013-12-31 (100%)Accession 0001193125-16-481707

Alerts are coming

Get an email when Orexigen Therapeutics, Inc.'s disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.